Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
McKinsey
Harvard Business School
Moodys
McKesson

Last Updated: January 27, 2023

Fenofibrate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for fenofibrate and what is the scope of freedom to operate?

Fenofibrate is the generic ingredient in nine branded drugs marketed by Lupin, Sun Pharm Inds Ltd, Ajanta Pharma Ltd, Alembic Pharms Ltd, Ani Pharms, Apotex, Aurobindo Pharma Ltd, Dr Reddys Labs Sa, Glenmark Pharms Ltd, Impax Labs, Invagen Pharms, Mylan Pharms Inc, Novast Labs, Reyoung, Rhodes Pharms, Rising, Torrent, Abbvie, Cipher Pharms Inc, Alembic Labs, Amneal, Aurobindo Pharma, Austarpharma, Cipla, Dr Reddys, Graviti Pharms, Hetero Labs Ltd Iii, Lupin Ltd, Mankind Pharma, Mylan, Prinston Inc, Sun Pharm, Valeant Pharms North, Salix, Abbvie Inc, and Skyepharma Ag, and is included in fifty NDAs. There are eight patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Fenofibrate has one hundred and ninety-five patent family members in thirty countries.

There are forty-two drug master file entries for fenofibrate. Fifty-one suppliers are listed for this compound. There is one tentative approval for this compound.

Drug Prices for fenofibrate

See drug prices for fenofibrate

Drug Sales Revenue Trends for fenofibrate

See drug sales revenues for fenofibrate

Recent Clinical Trials for fenofibrate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Phase 4
University of Colorado, DenverPhase 4
Mario Luca MorieriN/A

See all fenofibrate clinical trials

Generic filers with tentative approvals for FENOFIBRATE
Applicant Application No. Strength Dosage Form
See Plans and PricingSee Plans and Pricing130MGCAPSULE; ORAL
See Plans and PricingSee Plans and Pricing43MGCAPSULE; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for fenofibrate
Medical Subject Heading (MeSH) Categories for fenofibrate
Paragraph IV (Patent) Challenges for FENOFIBRATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FENOGLIDE Tablets fenofibrate 40 mg and 120 mg 022118 1 2010-03-17
ANTARA (MICRONIZED) Capsules fenofibrate 43 mg and 130 mg 021695 1 2008-09-15
TRICOR Tablets fenofibrate 48 mg 021656 1 2008-07-01
TRICOR Tablets fenofibrate 145 mg 021656 1 2007-10-19

US Patents and Regulatory Information for fenofibrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs Sa FENOFIBRATE (MICRONIZED) fenofibrate CAPSULE;ORAL 090859-002 Mar 1, 2012 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Abbvie TRICOR (MICRONIZED) fenofibrate CAPSULE;ORAL 019304-002 Feb 9, 1998 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Mylan FENOFIBRATE fenofibrate TABLET;ORAL 076520-002 Dec 29, 2005 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Salix FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Prinston Inc FENOFIBRATE fenofibrate TABLET;ORAL 211080-002 Aug 28, 2018 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for fenofibrate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc TRICOR fenofibrate TABLET;ORAL 021203-001 Sep 4, 2001 See Plans and Pricing See Plans and Pricing
Cipher Pharms Inc LIPOFEN fenofibrate CAPSULE;ORAL 021612-003 Jan 11, 2006 See Plans and Pricing See Plans and Pricing
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 See Plans and Pricing See Plans and Pricing
Abbvie Inc TRICOR fenofibrate TABLET;ORAL 021203-003 Sep 4, 2001 See Plans and Pricing See Plans and Pricing
Cipher Pharms Inc LIPOFEN fenofibrate CAPSULE;ORAL 021612-001 Jan 11, 2006 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for fenofibrate

Country Patent Number Title Estimated Expiration
Taiwan 200403079 Nanoparticulate fibrate formulations See Plans and Pricing
China 1867321 A solid dosage form comprising a fibrate See Plans and Pricing
World Intellectual Property Organization (WIPO) 2005034920 See Plans and Pricing
Japan 2010280685 NANOPARTICULATE COMPOSITION OF MAP KINASE INHIBITOR See Plans and Pricing
Canada 2719811 FORMES GALENIQUES DE FENOFIBRATE (FENOFIBRATE DOSAGE FORMS) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Mallinckrodt
Dow
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.